Dev Prasad
Stock Analyst at Lucid Capital
(4.59)
# 998
Out of 5,088 analysts
21
Total ratings
55%
Success rate
56.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TTRX Turn Therapeutics | Initiated Coverage: Buy | $24 | $10.72 | +123.88% | 1 | Sep 24, 2026 | |
| GNLX Genelux | Initiated Coverage: Buy | $18 | $2.10 | +757.14% | 1 | Sep 16, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $59 | $18.75 | +214.67% | 1 | Sep 14, 2026 | |
| ANL Adlai Nortye Group | Initiated Coverage: Buy | $49 | $10.28 | +376.65% | 1 | Sep 8, 2026 | |
| ELOX Eloxx Pharmaceuticals | Initiated Coverage: Buy | $38 | $13.20 | +187.88% | 1 | Aug 20, 2026 | |
| PLYX Polaryx Therapeutics | Initiated Coverage: Buy | $7 | $1.86 | +276.34% | 1 | Jul 27, 2026 | |
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $4.15 | +622.89% | 1 | May 4, 2026 | |
| ABOS Acumen Pharmaceuticals | Initiated Coverage: Buy | $6 | $2.29 | +162.01% | 1 | Dec 17, 2025 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $49 → $212 | $151.58 | +39.86% | 2 | Dec 15, 2025 | |
| IFRX InflaRx | Reiterated: Buy | $24 | $1.72 | +1,299.42% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $3.42 | +455.56% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4.00 | $0.48 | n/a | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $1 | $5.37 | n/a | 1 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $21.45 | n/a | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $3.65 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $2.70 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $5.03 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $7.44 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $1.75 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $0.8136 | n/a | 1 | Dec 17, 2024 |
Turn Therapeutics
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $10.72
Upside: +123.88%
Genelux
Sep 16, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $2.10
Upside: +757.14%
Faeth Therapeutics
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $59
Current: $18.75
Upside: +214.67%
Adlai Nortye Group
Sep 8, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $10.28
Upside: +376.65%
Eloxx Pharmaceuticals
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $38
Current: $13.20
Upside: +187.88%
Polaryx Therapeutics
Jul 27, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.86
Upside: +276.34%
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $4.15
Upside: +622.89%
Acumen Pharmaceuticals
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $6
Current: $2.29
Upside: +162.01%
Palvella Therapeutics
Dec 15, 2025
Reiterated: Buy
Price Target: $49 → $212
Current: $151.58
Upside: +39.86%
InflaRx
Nov 10, 2025
Reiterated: Buy
Price Target: $24
Current: $1.72
Upside: +1,299.42%
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $3.42
Upside: +455.56%
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.48
Upside: n/a
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $5.37
Upside: n/a
Aug 25, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $21.45
Upside: n/a
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $3.65
Upside: n/a
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $2.70
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $5.03
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $7.44
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $1.75
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $0.8136
Upside: n/a